| scholarly article | Q13442814 |
| P50 | author | Benjamin R Thomson | Q63615237 |
| P2093 | author name string | Yang Wei | |
| George D Yancopoulos | |||
| Susan E Quaggin | |||
| Xiaozhong Qian | |||
| Gavin Thurston | |||
| Nicholas Papadopoulos | |||
| John S Rudge | |||
| Christopher Daly | |||
| Samuel Davis | |||
| Elizabeth Pasnikowski | |||
| Carla Castanaro | |||
| Xiabo Jiang | |||
| P2860 | cites work | Angiopoietins 3 and 4: diverging gene counterparts in mice and humans | Q22008836 |
| Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning | Q24310148 | ||
| Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis | Q24313372 | ||
| Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation | Q24316945 | ||
| Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor | Q24323189 | ||
| Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts | Q24323888 | ||
| A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state | Q24564642 | ||
| Angiopoietin-1 is essential in mouse vasculature during development and in response to injury | Q24629743 | ||
| Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans | Q25255098 | ||
| Structural basis for angiopoietin-1-mediated signaling initiation | Q27677414 | ||
| Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity | Q28241585 | ||
| Structure of the angiopoietin-2 receptor binding domain and identification of surfaces involved in Tie2 recognition | Q28250689 | ||
| Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway | Q28256355 | ||
| Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation | Q28265004 | ||
| Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis | Q28300359 | ||
| Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1 | Q28513759 | ||
| Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 | Q28570936 | ||
| Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo | Q28586040 | ||
| Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling | Q30514534 | ||
| Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis | Q30541878 | ||
| Tie1 controls angiopoietin function in vascular remodeling and inflammation | Q30805233 | ||
| Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. | Q31882438 | ||
| Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency | Q33373012 | ||
| Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy | Q45058820 | ||
| Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins | Q45251408 | ||
| Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator of Vascular Inflammation | Q46142052 | ||
| Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation | Q46931416 | ||
| Activated protein C binds directly to Tie2: possible beneficial effects on endothelial barrier function. | Q48125007 | ||
| Stereological and immunogold studies on TIE1 and TIE2 localization in glomeruli indicate angiopoietin signaling in podocytes. | Q49111564 | ||
| Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis | Q50232021 | ||
| tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors | Q52230413 | ||
| Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. | Q53562021 | ||
| Thrombin induces the release of angiopoietin-1 from platelets. | Q55034619 | ||
| Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. | Q55062462 | ||
| Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy. | Q64933321 | ||
| Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C | Q71854044 | ||
| Platelet factor 4 enhances generation of activated protein C in vitro and in vivo | Q73062428 | ||
| Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway | Q73333644 | ||
| Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway | Q73586047 | ||
| Protein C activation and factor Va inactivation on human umbilical vein endothelial cells | Q73965821 | ||
| Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer | Q83069293 | ||
| Normal ranges of angiogenesis regulatory proteins in human platelets | Q84469561 | ||
| Angiopoietin-2 promotes myeloid cell infiltration in a β₂-integrin-dependent manner | Q84831062 | ||
| Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition | Q85428242 | ||
| Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial | Q88123697 | ||
| Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. | Q33620110 | ||
| Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands | Q33736879 | ||
| Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway | Q33896998 | ||
| The role of angiopoietins as potential therapeutic targets in renal cell carcinoma | Q33912405 | ||
| The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications | Q34060608 | ||
| Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. | Q34122609 | ||
| Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy | Q34344165 | ||
| Angiopoietin-2-driven vascular remodeling in airway inflammation | Q34358380 | ||
| Angiopoietin-2 is critical for cytokine-induced vascular leakage | Q34935131 | ||
| Endothelial destabilization by angiopoietin-2 via integrin β1 activation. | Q35047913 | ||
| Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells | Q35070344 | ||
| Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. | Q35345503 | ||
| Activated protein C: biased for translation. | Q35583397 | ||
| Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge | Q35990619 | ||
| The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway | Q36186523 | ||
| Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis | Q36295017 | ||
| Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis* | Q36994658 | ||
| Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation | Q37217491 | ||
| The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. | Q37331775 | ||
| Admission angiopoietin levels in children with septic shock. | Q37367802 | ||
| Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system | Q37398561 | ||
| Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death | Q37401041 | ||
| Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). | Q38341473 | ||
| Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway | Q38525872 | ||
| Therapeutic targeting of the angiopoietin-TIE pathway | Q39321127 | ||
| Amelioration of sepsis by TIE2 activation-induced vascular protection. | Q39835320 | ||
| Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. | Q40374532 | ||
| Angiopoietin-1 protects the adult vasculature against plasma leakage. | Q40890338 | ||
| Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. | Q41032918 | ||
| Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity | Q41634216 | ||
| Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex | Q42152403 | ||
| Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators | Q42504250 | ||
| Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin | Q42984086 | ||
| Association of Ang-2 with integrin beta 2 controls Ang-2/PDGF-BB-dependent upregulation of human peripheral blood monocyte fibrinolysis | Q43281528 | ||
| Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis | Q43559207 | ||
| Direct cell adhesion to the angiopoietins mediated by integrins | Q43603092 | ||
| Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. | Q44166149 | ||
| Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering | Q44240662 | ||
| Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors | Q44649604 | ||
| The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies | Q44771602 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 505 | |
| P577 | publication date | 2018-01-11 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Angiopoietins bind thrombomodulin and inhibit its function as a thrombin cofactor | |
| P478 | volume | 8 |
Search more.